Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
This article was originally published in PharmAsia News
Executive Summary
Sanofi Aventis reported second quarter net sales up 6.5 percent at constant exchange rates, despite the early impact of generic competition in Europe on the heart drug Plavix (clopidogrel), anti-hypertensive Aprovel (irbesartan), and cancer drug Eloxatin (oxaliplatin)